Schering-Plough’s Low AE Profile For Boceprevir Phase II Could Be Advantage Over Vertex’s Telaprevir In HCV Race
This article was originally published in The Pink Sheet Daily
Executive Summary
Vertex tells “The Pink Sheet” DAILY that VX-950 has more robust data, including new numbers scheduled for release at a major medical meeting next month.
You may also be interested in...
Schering-Plough Lays Out Phase III Plan For HCV Therapy Boceprevir
Surprise move pre-dates final Phase II SPRINT-1 data, closes gap with Vertex’s telaprevir.
Schering-Plough Lays Out Phase III Plan For HCV Therapy Boceprevir
Surprise move pre-dates final Phase II SPRINT-1 data, closes gap with Vertex’s telaprevir.
Protease Inhibitors Line Up To Challenge Vertex In HCV
In-class skirmish likely as combo therapy evolves, analyst tells “The Pink Sheet” DAILY.